fluorouracil and Purpura, Thrombotic Thrombocytopenic
fluorouracil has been researched along with Purpura, Thrombotic Thrombocytopenic in 8 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Purpura, Thrombotic Thrombocytopenic: An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this large pooled analysis, we found MMC, when capped at a cumulative dose of 36 mg/m(2), to be safe and tolerable in combination with capecitabine or irinotecan with no reportable cases of TTP/HUS." | 2.46 | Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials. ( Arce-Lara, C; Bekaii-Saab, T; Cataland, S; Kraut, E; Ntukidem, N; Otterson, GA, 2010) |
| "The patient was diagnosed with thrombotic thrombocytopenic purpura and treated with a plasma exchange." | 1.43 | [A Case of Thrombotic Thrombocytopenic Purpura in a Patient Undergoing FOLFOX6 plus Panitumumab Therapy for Unresectable Recurrent Rectal Cancer with a Rapidly Progressive Course]. ( Hatano, Y; Ishibashi, M; Kato, K; Konda, R; Michishita, Y; Nozawa, T; Oyama, K; Sasaki, A, 2016) |
| "Moreover, circulating tumor cells were demonstrated by flow cytometry." | 1.38 | [Severe hemorrhage in a patient with metastatic colorectal cancer - case 8/2012]. ( Horger, M; Jaschonek, K; Kanz, L; Kopp, HG; Kurth, R; Mayer, F; Orgel, M, 2012) |
Research
Studies (8)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Kato, K | 1 |
| Michishita, Y | 1 |
| Oyama, K | 1 |
| Hatano, Y | 1 |
| Nozawa, T | 1 |
| Ishibashi, M | 1 |
| Konda, R | 1 |
| Sasaki, A | 1 |
| Ntukidem, N | 1 |
| Arce-Lara, C | 1 |
| Otterson, GA | 1 |
| Kraut, E | 1 |
| Cataland, S | 1 |
| Bekaii-Saab, T | 1 |
| Kadikoylu, G | 1 |
| Barutca, S | 1 |
| Tataroglu, C | 1 |
| Kafkas, S | 1 |
| Erpek, H | 1 |
| Meydan, N | 1 |
| Yavasoglu, I | 1 |
| Bolaman, Z | 1 |
| Ferrand, FR | 1 |
| Gontier, E | 1 |
| Guymar, S | 1 |
| Fagot, T | 1 |
| Ceccaldi, B | 1 |
| Malfuson, JV | 1 |
| de Revel, T | 1 |
| Baudin, F | 1 |
| Guillot, P | 1 |
| Bedock, B | 1 |
| Blanc, PL | 1 |
| Orgel, M | 1 |
| Horger, M | 1 |
| Kurth, R | 1 |
| Kanz, L | 1 |
| Jaschonek, K | 1 |
| Mayer, F | 1 |
| Kopp, HG | 1 |
| Niu, J | 1 |
| Mims, MP | 1 |
| Barton, JC | 1 |
| Saway, DA | 1 |
| Blackburn, WD | 1 |
| Fallahi, S | 1 |
| Jakes, JT | 1 |
| Alarcón, GS | 1 |
Reviews
2 reviews available for fluorouracil and Purpura, Thrombotic Thrombocytopenic
| Article | Year |
|---|---|
Capped-dose mitomycin C: a pooled safety analysis from three prospective clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic | 2010 |
Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Other Studies
6 other studies available for fluorouracil and Purpura, Thrombotic Thrombocytopenic
| Article | Year |
|---|---|
[A Case of Thrombotic Thrombocytopenic Purpura in a Patient Undergoing FOLFOX6 plus Panitumumab Therapy for Unresectable Recurrent Rectal Cancer with a Rapidly Progressive Course].
Topics: ADAM Proteins; ADAMTS13 Protein; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
Thrombotic thrombocytopenic purpura as the first manifestation of metastatic adenocarcinoma in a young woman.
Topics: Abdomen, Acute; Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Bio | 2010 |
Effectiveness and safe use of modified FOLFOX-6 for metastatic gastric cancer with signet ring cell components complicated by disseminated intravascular coagulation and diffuse bone marrow carcinomatosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma; Carcinoma, Signet | 2012 |
[Refractory thrombotic thrombocytopenic purpura revealing an epiglotis neoplasia].
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; An | 2012 |
[Severe hemorrhage in a patient with metastatic colorectal cancer - case 8/2012].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
Thrombotic thrombocytopenic purpura in systemic sclerosis.
Topics: Adult; Female; Fluorouracil; Humans; Purpura, Thrombotic Thrombocytopenic; Scleroderma, Systemic | 1989 |